MabCure, Inc. (MBCI)

[WoollenBlock48]

That's my order of 55,555. I tried slapping .005 but then it just let me have it after I changed it

[$treet Trader]

MBCI .004 x .005 should have more updates coming

[WoollenBlock48]

This could run really really hard

[$treet Trader]

MBCI .006 up thinned out

[funnyG986]

MBCI VNDM ON BIDS @0.0045

[funnyG986]

MBCI boommmmmmmmm 0.006 is up

[$treet Trader]

MBCI .0045 x .006

[funnyG986]

Last seller below 0.005; anything here is a gift MBCI heading to penny

[$treet Trader]

MBCI .005

[funnyG986]

MBCI watch for 0.005 break here. Most ppl are still waiting for en entry here

[$treet Trader]

MBCI looking real thin here

[funnyG986]

MBCI 0.0047 up

[funnyG986]

MBCI moves on air!!! 0.0045 50k left

[$treet Trader]

MBCI .0045

[funnyG986]

MBCI 0.004 x 0.0045

[funnyG986]

MBCI looking for a break here. 0.004 so THIN

[$treet Trader]

MBCI .004

[$treet Trader]

MBCI looking real thin

[funnyG986]

MBCI 0.0039 X 0.004

[$treet Trader]

MBCI looks like merger coming

[funnyG986]

MBCI 0.003 x 0.0034 BIDS STACKING NOW

[$treet Trader]

sweet, MBCI looks like merger coming

[funnyG986]

MBCI 8K OUT AH; change of control is now official

Item 5.01 Change of Control of Registrant.

See Item 5.02.

On May 21, 2015, Jehu Hand was appointed custodian of Mabcure Inc. by the


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 21, 2015, Jehu Hand was appointed custodian of Mabcure Inc. by the Nevada District Court pursuant to Nevada Revised Statutes 78.347 (Case Number A-15-716907-B). As custodian, Mr. Hand appointed himself as the new Board of Directors, and the Board appointed him as Chief Executive and Financial Officer and Kimberly Peterson as corporate Secretary. Since Mabcure Inc. is a voluntary filer, there are no plans to file any periodic reports or further reports with the Securities and Exchange Commission.

http://www.sec.gov/Archives/edgar/data/1388490/000100233415000044/f8kmanagementchange1.htm

[$treet Trader]

MBCI .004 going just got reinstated

[$treet Trader]

MBCI .004 reinstated 60M OS

[$treet Trader]

in MBCI reinstated 60M OS

http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=1qJYH9WMBGpEdLmAl%252f5RXw%253d%253d&CorpName=MABCURE+INC.

[Renee]

MBCI is severely delinquent in filing their Financials and corporate filing obligations to the SEC. On Feb. 20, 2015 the SEC suspended 8 stocks from the Delinquent SEC Filers list, and it is likely that more delinquent Filers will be suspended.

Since Jan 1st, 2010 the SEC has suspended over 1290 stocks for Financials delinquencies. All of those Suspended stocks had their stock registrations revoked.

Shareholders should contact the company and pressure the Mgmt to file their delinquent Financials because ALL shareholders would be wiped out IF the SEC suspends the stock.

MBCI is on the list of delinquent filers:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110680509

[helpus]

lets see what you can do

[hubba hubba]

a diamond in the rough

[hubba hubba]

this one just needs a small nudge and it'll fly

[kranthikumar]

MBCI is looking great at this level

[kranthikumar]

MBCI is looking great at this level

[trader53]

MBCI 0.004

http://www.allotcbb.com/quote.php?symbol=mbci

Share Structure
Market Value1........................$257,456 a/o Dec 04, 2013
Authorized Shares...............1,500,000,000
Shares Outstanding.................64,363,902 a/o Mar 31, 2012
Float Not Available
Par Value 0.001
http://www.otcmarkets.com/stock/MBCI/filings
http://www.otcmarkets.com/stock/MBCI/company-info

http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=1qJYH9WMBGpEdLmAl%252f5RXw%253d%253d
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=1qJYH9WMBGpEdLmAl%252f5RXw%253d%253d&CorpName=MABCURE+INC.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93424350

http://stockcharts.com/h-sc/ui?s=MBCI&p=D&yr=1&mn=0&dy=0&id=p71018875850
http://stockcharts.com/h-sc/ui?s=MBCI&p=D&yr=1&mn=8&dy=0&id=p21596174833

[MikeCr]

What's up with all the trading volume in the last few days.
Over a million shares today. Some one bought 404,000 shares @ 0.004
Is this company still in business? They don't even have a website anymore and no news since 2011.

[trader53]

MBCI 0.0042 - Targets 0.009 / 0.02 / 0.025

Buy at 0.002, or less
http://stockcharts.com/h-sc/ui?s=MBCI&p=D&yr=1&mn=7&dy=0&id=p77055734480

Research Links:

Company Search:
http://www.otcmarkets.com/news/otc-news

http://www.otcbb.com/asp/Info_Center.asp

Press Releases Search:
http://www.macreportmedia.com/SubmissionResults.aspx

Business Entity Search:
http://investorshub.advfn.com/The-Secretary-of-State-(SOS)-19900/

http://nvsos.gov/sosentitysearch/CorpSearch.aspx

A/S Authorized Shares Search:
http://investorshub.advfn.com/Dilution-Watching-&-Huge-AS-Warning-25935/

Technical Search:
http://www.allotcbb.com/

http://www.stockta.com/

[MikeCr]

What happened today with the very high volume near 300,000 shares and the pps up 120%?
Any news?

[kranthikumar]

MBCI is up by 100%

[kranthikumar]

MBCI is exactly up by 100%

[MikeCr]

stein, you're right that news from Mabcure is overdue.

While we wait for that, check out Arrayit Corp. (ARYC) which is a company that is developing a screening test for Ovarian cancer.

They have announced that their OvaDx test is around 90% sensitivity and 100% specific i.e there are no false positives with this test and it finds 9 out 10 ovarian cancers of all types and stages (I thru IV).

SUNNYVALE, Calif., April 4, 2012 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB: ARYC) and Arrayit Diagnostics, Inc. ("AD") report significant results from a 257 patient research study on its pre-symptomatic ovarian cancer molecular diagnostic test in development, OvaDx®. In this study, OvaDx® recorded sensitivity of 79.7%, correctly identifying patients known to have cancer, and specificity approaching 100%, correctly identifying the healthy controls, patients known not to have cancer.

"We continue to make additional enhancements subsequent to this pilot study that indicate improvements in the sensitivity number approaching 90%. We are working to make this diagnostic test superior to any existing test. Requiring only a finger stick of blood, this will also be the easiest test to administer," says Dr. Mark Schena, President and Chief Scientific Officer of Arrayit Corporation."

Since July of 2009, AD has operated as an independent subsidiary of Arrayit Corporation and holds all the intellectual property, licenses and development agreement assets related to the pre-symptomatic ovarian cancer diagnostic test known as OvaDx®. On December 14th, 2011, Arrayit Corporation announced the spin-off of AD and the distribution of its 78.18% interest in AD as a stock dividend to ARYC shareholders. The record date, dividend distribution date and further details will be announced shortly.
------------------

Check out recent tweets on their twitter feed. ARYC stock is now 0.25 but it's bound to go higher soon.

www.twitter.com/arrayit

[steinny11]

It's Been 8 Months Now, Results Coming Soon?

Small companies like this are always late on results. When should we expect news about the Ovarian Cancer Diagnostic Study in Thailand?

I'm hoping soon!

[steinny11]

I agree, we don't get infomation very often which can be frustrating. But, I wouldn't expect to hear anything until they have something to report. In December they said it would be about 6 months for results which means we should hear something in June. Of course, I don't expect those results to be on time but giving up now seems premature. I'm giving it another 3 months in hopes of a press release on (hopefully really positive) results.

[Jragin]

Well that's it. I should have got out when Dr. Orr quit. $27,000 dollars down the toilet on this company. What kind of bozos never give any investor info after so many months? I hope to hell that you Mabcure guys tried your very best to find your cancer markers and that it was not all just screw your investors. Since you never write to US, WE HAVE NO IDEA WHAT OUR MONEY WAS USED FOR. WRITE A DAMN NOTE TO YOUR INVESTORS! WRITE IT!

[CEOA1US]

No he Dr. Gonenne is still CEO. I think he's in it for the long haul.

[Jragin]

Sorry! It was Dr Orr that quit! Dr. Orr was the developer of the MabCure technology and the novel MAbs.

[Jragin]

Why is Dr. Amnon Gonenne being quoted as supporting this announcement like he is the CEO? I thought he quit long ago?

[MikeCr]

MabCure Announces Completion of Its Ovarian Cancer Diagnostic Study in Thailand
Data Analysis Expected to be Completed in Six Months


Press Release: MabCure, Inc. – Thu, Dec 15, 2011 2:09 PM EST

http://finance.yahoo.com/news/MabCure-Inc-Announces-bw-1598504181.html?x=0

[DeadCellShadix]

The PR is nice, nice enough for me to square away a pretty sizeable position here, now we wait. Hopefully more news to come.

[V63]

Maybe because anticipated PR that came out today...not to shabby..huh?

[John15]

Up 69% on the day ... more room to run?

[MikeCr]

MabCure Receives U$500,000.00 Licensing Fee as Well as 12.5% Ongoing Royalty for Its Prostate Cancer Diagnostic Technology

Nov 22 2011 NEW YORK--(BUSINESS WIRE)-- MabCure, Inc. (OTCBB: MBCI.OB - News), a leading developer of antibody-based diagnostics and treatments for ovarian and prostate cancer, today announced that it has signed a license agreement with Biotech Investment Corp. (“Biotech”), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15% of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5% on revenues.

The need for a new method for diagnosing prostate cancer has become evident recently due to the major controversy over the usefulness of PSA testing. PSA is a marker of inflammation of the prostate, not of prostate cancer, and, as such, it is not surprising that repeated clinical studies have shown that PSA testing fails to alter the survival rate of prostate cancer patients. MabCure’s antibodies are aimed at prostate cancer markers and as such may have the potential for yielding an accurate diagnosis of prostate cancer.

Dr. Amnon Gonenne, CEO of MabCure, commented: “This is a very exciting deal for MabCure and its shareholders. It demonstrates the confidence of our investors (Biotech) in our technology and the early proof of concept attained with our antibodies for the diagnosis of ovarian cancer. The license fee will mainly be used to further the development and testing of our hybridoma clones for the diagnosis of Ovarian Cancer. We look forward to working with Biotech on developing the prostate cancer diagnostic test and are excited about the parallel development and testing of our antibodies for the detection and treatment of two forms of cancer.”